Hepatosplenic T-cell lymphoma: treatment challenges.
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
01 09 2021
01 09 2021
Historique:
entrez:
19
8
2021
pubmed:
20
8
2021
medline:
14
1
2022
Statut:
ppublish
Résumé
Hepatosplenic lymphoma (HSTCL) is a rare T-cell malignancy occurring in young males, associated with immune deficiency in 20% of the cases which, despite aggressive treatments, has a poor survival. Specific recommendations for first-line treatment remain debatable. Published data covering case reports or series of HSTCL concur that allogeneic stem cell transplant should be proposed as a consolidation after response to chemotherapy in all patients eligible for transplant. In the light of two recent clinical examples, we also confirm that specific chemotherapy and a first-line consolidation with allogeneic transplantation when a donor is available to represent a treatment of choice these rare and distinctive lymphomas. Recent molecular studies are summarized in this review and suggest potential targets for new therapeutic strategies. Major progresses have been achieved in improving the outcome of HSTCL l patients using intensive chemotherapy and allogeneic transplantation.
Identifiants
pubmed: 34409955
doi: 10.1097/CCO.0000000000000775
pii: 00001622-202109000-00004
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
406-411Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World HealthOrganisation classification oflymphoid neoplasms. Blood 2016; 127:2375–2390.
Foss FM, Horwitz SM, Civallero M, et al. Incidence and outcomes of rare T cell lymphomas from the T cell project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. Am J Hematol 2020; 95:151–155.
Shah ED, Coburn ES, Nayyar A, et al. Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from Food and Drug Administration A dverse Event Reporting System. Aliment Pharmacol Ther 2020; 51:527–533.
Pro B, Allen P, Behdad A. Hepatosplenic T-cell lymphoma: a rare but challenging entity. Blood 2020; 136:2018–2026.
Weidmann E. Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in. Leukemia 2000; 14:991–997.
Travert M, Huang Y, de Leval L, et al. Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic target. Blood 2012; 169:5795–5806.
Nicolae A, Xi L, Pittaluga S, et al. Frequent STAT5B mutations in γδ hepatosplenic T-cell lymphomas. Leukemia 2014; 28:2244–2248.
Soria-López E, Casanova-Espinosa M, Fernández Pérez F. Hepatosplenic T-cell lymphoma (HSTCL) in patient with Crohn's disease treated with azathioprin. Med Clin (Barc) 2021; 156:579–580.
Dahmus J, Rosario M, Clarke K. Risk of lymphoma associated with Anti-TNF therapy in patients with inflammatory bowel disease: implications for therapy. Clin Exp Gastroenterol 2020; 13:339–350.
Pin Chuen Zing, Thais Fischer, Jasmine Zain, et al. Peripheral T-cell lymphomas: incorporating new developments in diagnostics, prognostication, and treatment into clinical practice. PART 2: ENKTL, EATL, indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell Lymphoma , Peripheral T-Cell Lymphomas. Oncology (Williston Park) 2018; 32:e83–e89.
Bojanini L, Jiang L, Tun AJ, et al. Outcomes of hepatosplenic T-cell lymphoma: The Mayo clinic experience. Clin Lymphoma Myeloma Leuk 2021; 21:106–112.
Ramalho SA, Abecasis F, Santos L, et al. Hypercalcaemia: an extremely rare presentation of hepatosplenic T-cell lymphoma. Eur J Case Rep Intern Med 2021; 8:002360.
Finalet Ferreiro J, Rouhigharabaei L, Urbankova H, et al. Integrative genomic and transcriptomic analysis identified candidate genes implicated in the pathogenesis of hepatosplenic T-cell lymphoma. PLoS One 2014; 9:e102977doi: 10.1371/journal.pone.0102977.
doi: 10.1371/journal.pone.0102977
Matthew McKinney, Andrea B. Moffitt, Philippe Gaulard, et al. The genetic basis of hepatosplenic T-cell lymphoma. Med Clin 2021; 156:579–580.
Drieux F, Ruminy P, Abdel-Sater A, et al. Defining signatures of peripheral T-cell lymphoma with a targeted 20-marker gene expression profiling assay. Haematologica 2020; 105:1582–1592.
Dina Milowich, Laurence de Leval. An update on the pathology of extranodal T-cell lymphomas. Diagnostic Histopathology 2020; 26:379–385.
Philip A Haddad, Dalia Hammoud, Kevin M. Gallagher. Epidemiology and Clinicopathology of Hepatosplenic T-Cell Lymphoma (HSTCL): Analysis of a Pooled Database - Blood 2020; 136:2076 (ASH Abstract). doi: https://doi.org/10.1182/blood-2020-136463 .
Yi-Hua Chen, LoAnn Peterson. Differential diagnosis of CD4-/CD8- γδ T-cell large granular lymphocytic leukemia and hepatosplenic T-cell lymphoma. Am Clin Pathol 2012; 137:496–497.
Aguilera NS, Auerbach A. T-cell lymphoproliferative processes in the spleen. Semin Diagn Pathol 2020; 37:47–56.
Philip A Haddad, Dalia Hammoud, Kevin M. Gallagher. Epidemiology and Clinicopathology of Hepatosplenic T-Cell Lymphoma (HSTCL): Analysis of a Pooled Database - Blood 2020; 136:2076 (ASH Abstract). doi: https://doi.org/10.1182/blood-2020-136463 .
Klebaner D, Koura D, Tzachanis D, et al. Intensive induction therapy compared with CHOP for hepatosplenic T-cell lymphoma. Clin Lymphoma Myeloma Leuk 2020; 20:431–437. e2.
Yabe M, Jeffrey Medeiros L, Guilin Tang, et al. Prognostic Factors of hepatosplenic T-cell lymphoma: clinicopathologic study of 28 cases. Am J Surg Pathol 2016; 40:676–688.
Julie Vose, James Armitage, Dennis Weisenburger. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26:4124–4130.
Jeffrey I. Cohen1, Elaine S. Jaffe, Janet K. Dale, et al. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood 2017; 117:5835–5849.
Lauhan CR, Schiff D, Gloude N. Successful treatment of hepatosplenic T cell lymphoma in an adolescent with Turner syndrome using ifosfamide, carboplatin, and etoposide followed by allogeneic hematopoietic stem cell transplant. Pediatr Blood Cancer 2020; 67:e28528doi: 10.1002/pbc.28528.
doi: 10.1002/pbc.28528
Lauren C. Pinter-Brown. Strategies for aggressive T-cell lymphoma: divide and conquer Hematology 2020 . Hematology Am Soc Hematol Educ Program 2020;1:154-159.
Martin H. Voss, Matthew A. Lunning, Jocelyn C. Maragulia, et al. Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clin Lymphoma Myeloma Leuk 2013; 13:8–14.
Thomas Luo, Timothy S. Fenske, Mehdi Hamadani, et al. Allogeneic transplant outcomes for T-cell lymphomas: a single center analysis. Blood 2020; 136: (Supplement 1): 20–21.
Rashidi A, Cashen AF. Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma. Blood Cancer J 2015; 5:e318DOI: 10.1038/bcj.2015.43.
doi: 10.1038/bcj.2015.43
2015; Tanase A, Schmitz N, Stein H, et al. on behalf of the Lymphoma Working Party of the EBMT. Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party Leukemia. 29:686–688.
Iwaki N, Mochizuki K, Ozaki J, et al. A case of hepatosplenic T-cell lymphoma successfully treated by HLA haploidentical stem cell transplantation. J Clin Exp Hematop 2020; 60:55–59.
Neha Mehta-Shah. Successful treatment of mature T cell lymphoma with allogeneic stem cell transplantation: the largest multicenter retrospective analysis . Blood 2020;136:(ASH Abstract).
Horwitz SM, Ansell S, Ai WZ, et al. NCCN guidelines insights: T-cell lymphomas, Version 1.2021. J Natl Compr Canc Netw 2020; 18:1460–1467.
Gulati N, Béguelin W, Giulino-Roth L. Enhancer of Zeste Homolog 2 (EZH2) inhibitors. Leuk Lymphoma 2018; 59:1574–1585.
Pikman Y, Conway AS, Robichaud AL, et al. Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma. Blood Adv 2020; 4:1265–1269.
Dhir A, Hill B, Waite ES, et al. Pralatrexate-based therapy induced response in an adolescent with refractory hepatosplenic T-cell lymphoma. Pediatr Blood Cancer 2020; 67:e28460doi: 10.1002/pbc.28460.
doi: 10.1002/pbc.28460
Ng SY, Yoshida N, Christie AL, et al. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun 2018; 9:2024doi: 10.1038/s41467-018-04356-9.
doi: 10.1038/s41467-018-04356-9